ISSN: 1307-5888 | E-ISSN: 2757-7392 | Contact
The Prevalence of Metabolic Associated Fatty Liver Disease in The Turkish Population: A Multicenter Study
1Department of Gastroenterology, Marmara University, School of Medicine, Istanbul, Turkey
2Department of Internal Medicine, Division of Gastroenterology, SANKO University, School of Medicine, Gaziantep, Turkey
3Department of Gastroenterology, Mersin University, Faculty of Medicine, Mersin, Turkey
4Department of Gastroenterology, Gülhane Training and Research Hospital, Health Sciences University, Ankara, Turkey
5Department of Gastroenterology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey
6Department of Internal Medicine, Helios Hospital Schleswig, Academical Educational Hospital of Luebeck and Kiel Universities, Schleswig, Germany
7Department of Gastroenterology, Umraniye Training and Research Hospital, Health Sciences University, Istanbul, Turkey
8Department of Gastroenterology, School of Medicine, Ankara University, Ankara, Turkey
9Department of Gastroenterology, Sisli Hamidiye Etfal Training and Research Hospital, Health Sciences University, Istanbul, Turkey
10Department of Gastroenterology, School of Medicine, Koç University, İstanbul, Turkey
11Department of Gastroenterology, School of Medicine, Gazi University, Ankara, Turkey
12Deparment of Gastroenterology, Medical Park Hospital, Gaziantep, Turkey
Hepatology Forum - DOI: 10.14744/hf.2021.2020.0033
Full Text PDF


Background and Aim: The aim of the present study was to investigate the prevalence of metabolic associated fatty liver disease (MAFLD) in patients with dyspepsia.
Methods: Between January 2019 and December 2019, a total of 909 consecutive patients with complaint of dyspepsia were included.
Results: Their median age was 47 years. Among them, 30.3% of the patients were obese, 18.8% had type 2 diabetes mellitus, 35.1% had metabolic syndrome, 84.8% had dyslipidemia, and 23.9% had hypertension. The prevalence of MAFLD was found to be 45.5%. Among those patients with MAFLD prevalence of obesity, type 2 diabetes mellitus, metabolic syndrome, dyslipidemia, and hypertension were 43.3%, 24.9%, 52.5%, 92.3% and 31.9%, respectively. MAFLD was significantly associated with all the metabolic comorbidities (p<0.001). The median FIB-4 score of the MAFLD patients was 0.88 [0.1-9.5]. Of note, 53 patients with hepatic steatosis did not meet the MAFLD criteria.
Conclusion: based on the results of the present study, the prevalence of MAFLD is found to be significantly high in daily clinical practice in Turkey. Early diagnosis and prevention efforts should be aimed to reduce disease progression, which highlight application of a region based implementation strategy in our country.